Aldosterone synthase inhibitor
US10822332B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 26, 2017 |
| Grant date | Nov 3, 2020 |
| Priority date | — |
| Expiry date | Oct 26, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P13/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.